Human Cripto-1 as a target for a cancer vaccine: WO2008040759.
Human Cripto-1 is a cell membrane protein that has been shown to be overexpressed in different types of human tumors. Because Cripto-1 is expressed at low levels in normal tissues, it represents a promising candidate for therapeutic intervention in cancer. The present patent describes a novel approach to target Cripto-1 in cancer using a vaccine. Immunization with Cripto-1 modified by addition of a foreign peptide to overcome T-cell tolerance for self-proteins has the potential to generate an antibody-based immune response that ultimately will block Cripto-1 activity in cancer cells. Although targeting Cripto-1 with a vaccine in cancer patients is promising, several experimental and clinical studies need to be done to validate this approach.
Mammary Biology & Tumorigenesis Laboratory, National Cancer Institutes, National Institutes of Health, Bethesda, MD 20892, USA.
Caterina
C
Bianco
David S
DS
Salomon
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D016503:Drug Delivery Systems; D004815:Epidermal Growth Factor / Q000276:immunology*; D058851:GPI-Linked Proteins; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008562:Membrane Glycoproteins / Q000276:immunology*; D009363:Neoplasm Proteins / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D010330:Patents as Topic; D017634:Self Tolerance / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D019496:Cancer Vaccines; D058851:GPI-Linked Proteins; D036341:Intercellular Signaling Peptides and Proteins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C070636:TDGF1 protein, human; D004815:Epidermal Growth Factor